drugset / Trial / NCT06071624
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
Phase 1
Recruiting
30 enrolled
Huda Salman
The Leukemia and Lymphoma Society · collabiCell Gene Therapeutics · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in subjects with relapsed or refractory CMML. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells.
Timeline
- Start
- 2024-02-21
- Primary completion
- 2028-12
- Completion
- 2043-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD4CAR | Cell therapy | 800000 cells | Intravenous |